← Signal Board

Virax Biolabs Group financial statements

바이랙스 바이오랩스 그룹NASDAQ:VRAX · Nasdaq · Healthcare · sector #20
$1.99-5.69%
2026-10-08 close

Virax Biolabs Group's published financial data is dated 2026-10-04. 2025 revenue was $0M. 2025 operating profit was −$6M.

Reported results

Financial safety

Reference indicatorAs of 2025
Safe zoneFinancial-metric reference signal
Altman Z'' zoneZ'' 8.88
Distress
Grey
Safe
The marker shows the current Z'' value within the displayed zones.
Altman Z''
8.88
Beneish M-Score
-7.39

No statistical flag

Sloan accrual
-23.30%

부실·조작 위험을 나타내는 사실 지표입니다. 투자 조언이 아니며, 검증 전이라 참고용입니다.

Factual information, not investment advice.

Earnings quality · Piotroski F-Score

2/9Weak

Piotroski measures year-over-year financial improvement, not absolute quality.

Financial improvement score2/9

Profitability

  • Positive ROANot passed
  • Positive OCFNot passed
  • Improving ΔROAPass
  • Accruals (OCF > net income)Pass

Leverage & liquidity

  • Lower debtNot passed
  • Higher current ratioNot passed
  • No new sharesNot passed

Efficiency

  • Higher gross marginNot passed
  • Higher asset turnoverNot passed

Calculation note: F7(신주)은 equity/asset 유지로 근사

Already-stable companies may score lower when year-over-year improvement is limited.

Factual information, not investment advice.

Forensic signals

Anomaly and structural signals observed in the financial statements.

Revenue qualityDanger

매출 흑자인데 영업CF 적자 (OCF/매출 -72094%). 통계적 정황 신호이며 회계부정 단정이 아닙니다.

Balance sheetWarning

부채총계 급증 (+523%). 통계적 정황 신호이며 회계부정 단정이 아닙니다.

Margin trendWarning

영업이익률 악화 (-4153.2% → -97360.2%, -93207.0%p). 통계적 정황 신호이며 회계부정 단정이 아닙니다.

Factual information, not investment advice.

Risk sensitivity — adverse assumptions

Metric changes under stated assumptions; not a forecast or investment advice.

Base metrics

Operating margin
-97,360.2%
Interest coverage
-105.9x
Return on equity (ROE)
-106.4%

Operating margin −5pp

Operating loss
Interest coverageBase -105.9x adverse case -105.9x
Return on equity (ROE)Base -106.4% adverse case -109.2%

Revenue −15%

Interest coverage risk
Interest coverageBase -105.9x adverse case -90x
Return on equity (ROE)Base -106.4% adverse case -93%

Interest rate +2pp

Interest coverage risk
Interest coverageBase -105.9x adverse case -84.7x
Return on equity (ROE)Base -106.4% adverse case -109.5%

Interest coverage limit

Already below the limit by 98,279.3pp

Interest coverage limit at an operating margin of 919.1%

Interest expense coverage threshold

Virax Biolabs Group notifications

Quantus Signal · live data · not investment advice · Privacy Policy